Bausch + Lomb

363 articles about Bausch + Lomb

• Bausch + Lomb Reports More Than 41 Million Units Of Contact Lens, Eye And Lens Care Materials Recycled Through ONE By ONE And Biotrue® Eye Care Recycling Programs

  11/15/2021

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced its exclusive ONE by ONE and Biotrue® Eye Care Recycling programs have recycled a total of 41,358,603 million units, or 248,516 pounds, of used contact lens, eye and lens care materials.

• Bausch + Lomb Will Present Scientific Data and Analyses During the American Academy of Ophthalmology and American Academy of Optometry Annual Meetings

  11/1/2021

  Bausch + Lomb announced that seven scientific posters involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms surveillance study, will be presented during the annual meetings of the American Academy of Optometry in Boston and American Academy of Ophthalmology in New Orleans.

• Bausch + Lomb Launches Biotrue® Eye Care Recycling Program in Collaboration With TerraCycle in the United States

  10/27/2021

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the launch of the Biotrue® Eye Care Recycling program, the first and only eye care recycling program in the United States.

• Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

  10/25/2021

  XIPERE™ is the First and Only Medicine to be Approved in the United States for Delivery via Suprachoroidal Injection, a Method Designed to Facilitate Targeted Delivery of Therapeutic Agents to the Retina and Choroid

• 

  FDA Approves New Method for Macular Edema Treatment

  10/25/2021

  Xipere was approved for suprachoroidal use for the macular edema treatment. Macular edema is associated with uveitis, it is a form of eye inflammation.
• 

  FDA Action Alert: Pfizer-BioNTech, Oncopeptides, Eyenovia, ANI and More

  10/25/2021

  The U.S. FDA has a busy period at the end of October heading into the first week of November.
• 

  Clinical Catch-Up: October 4-8

  10/11/2021

  Another busy week for clinical trial news. Here’s a look.
• 

  Clinical Catch-Up: September 27-October 1

  10/4/2021

  It was a busy week for clinical trial news. Here’s a look.

• Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohexyloctane) in Dry Eye Disease Associated with Meibomian Gland Dysfunction

  9/30/2021

  Bausch + Lomb today announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational drug NOV03 (perfluorohexyloctane) as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).

• Bausch + Lomb Will Present 14 Scientific Posters Featuring New Analyses Involving Its Surgical Technologies At The 2021 Annual Meeting Of The American Society Of Cataract And Refractive Surgery

  7/19/2021

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the presentation of 14 scientific posters involving the company's ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting, which will take place from July 23-27, 2021, in Las Vegas.

• Bausch + Lomb Completes Enrollment Of Second Phase 3 Study For NOV03 (perfluorohexyloctane)

  7/7/2021

  Bausch + Lomb and Novaliq GmbH announced the second of two Phase 3 studies evaluating the investigational drug NOV03 as a first-in-class eye drop with a novel mechanism of action to treat the signs and symptoms of dry eye disease associated with meibomian gland dysfunction, has been completely enrolled with a total of 622 participants.

• Nicox’s Licensee Bausch + Lomb Receives Approval for VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in the United Arab Emirates

  6/25/2021

  Nicox SA, an international ophthalmology company, announced that its exclusive global licensee Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has received approval for VYZULTA®, 0.024% in the United Arab Emirates.

• Bausch + Lomb Expands Parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses

  6/23/2021

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced the U.S. launch of expanded parameters for Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses.

• Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of eyeTELLIGENCE™ Clinical Decision Support Software

  6/8/2021

  Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb's eyeTELLIGENCE™ clinical decision support software.

• Bausch + Lomb and Prevent Blindness Launch Educational Campaign During Cataract Awareness Month

  6/1/2021

  Organizations Also Launch Social Media Donation Program to Support Prevent Blindness and Broaden Patients' Access to Cataract Surgery and Care During June's Cataract Awareness Month

• New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced Age-Related Macular Degeneration Progression

  5/11/2021

  Results Provide New Evidence of the Recommended Formula Determined in the AREDS2 Study

• Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar

  5/4/2021

  Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA®(latanoprostene bunod ophthalmic solution), 0.024%in Taiwan and Receives Approval in Qatar

• 

  Clinical Catch-Up: April 12-16

  4/19/2021

  It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.

• FDA Approves Bausch + Lomb ClearVisc™ Dispersive Ophthalmic Viscosurgical Device

  4/7/2021

   Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the U.S. Food and Drug Administration (FDA) has approved ClearVisc™ dispersive ophthalmic viscosurgical device

• Bausch + Lomb Launches Alaway® Preservative Free Antihistamine Eye Drops

  2/23/2021

  First FDA-Approved OTC Preservative-Free Antihistamine Eye Drop Approved for Relief of Itchy Eyes Associated with Allergies Now Rolling out to Major U.S. Retailers